What is the treatment for Wolff-Parkinson-White (WPW) syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most effective treatment for Wolf-Parkinson-White (WPW) syndrome is catheter ablation, which is recommended as first-line therapy, especially for symptomatic patients or those with high-risk features, as it has success rates over 95% and low complication rates 1.

Treatment Options

The treatment for WPW syndrome focuses on managing abnormal heart rhythms caused by an extra electrical pathway in the heart. For acute episodes of tachycardia, the following options are available:

  • Vagal maneuvers like bearing down or coughing may help
  • Medications such as adenosine (6-12 mg IV) or calcium channel blockers like verapamil (5-10 mg IV)
  • Intravenous procainamide or ibutilide to restore sinus rhythm or slow the ventricular rate is recommended for patients with pre-excited AF and rapid ventricular response who are not hemodynamically compromised 1

Long-term Management

Long-term management includes:

  • Antiarrhythmic medications such as flecainide (50-200 mg twice daily), propafenone (150-300 mg three times daily), or beta-blockers like metoprolol (25-100 mg twice daily)
  • Catheter ablation of the accessory pathway is recommended in symptomatic patients with pre-excited AF, especially if the accessory pathway has a short refractory period that allows rapid antegrade conduction 1

Important Considerations

Patients should avoid triggers like excessive caffeine, alcohol, and stress, and should seek immediate medical attention for severe symptoms like chest pain, severe shortness of breath, or fainting. Regular follow-up with a cardiologist is essential to monitor the condition and adjust treatment as needed. In cases of hemodynamic instability, immediate direct-current cardioversion is recommended to prevent ventricular fibrillation in patients with a short anterograde bypass tract refractory period in whom AF occurs with a rapid ventricular response 1.

From the Research

Treatment Options for Wolff-Parkinson-White Syndrome

The treatment for Wolff-Parkinson-White (WPW) syndrome can vary depending on the severity of the symptoms and the type of arrhythmia present.

  • Medical therapy is often the first line of treatment, with medications such as propranolol 2, digitalis 2, and flecainide 3 being used to control symptoms.
  • For patients with atrial fibrillation or flutter, medications such as flecainide 3, propafenone, and amiodarone can be used to slow conduction over the accessory pathway.
  • In emergencies, adenosine can be used to terminate atrioventricular reciprocating tachycardia (AVRT) 4.
  • For patients who do not respond to medical therapy, catheter ablation using radiofrequency energy is a highly effective treatment option 4.
  • Surgical ablation is also an option for patients who are not candidates for catheter ablation or who have undergone failed catheter ablation 4.

Medications Used in Treatment

  • Propranolol: a beta-blocker that can be used to control symptoms of WPW syndrome, particularly in patients with orthodromic AVRT 2, 5.
  • Digitalis: can be used to control symptoms of WPW syndrome, particularly in patients with atrial fibrillation or flutter 2.
  • Flecainide: a Class IC antiarrhythmic agent that can be used to slow conduction over the accessory pathway and prevent AVRT 3.
  • Amiodarone: a Class III antiarrhythmic agent that can be used to slow conduction over the accessory pathway and prevent AVRT 4.

Non-Pharmacological Treatments

  • Catheter ablation: a highly effective treatment option for patients with WPW syndrome, particularly those who do not respond to medical therapy 4.
  • Surgical ablation: an option for patients who are not candidates for catheter ablation or who have undergone failed catheter ablation 4.
  • Artificial pacemaker: may be considered in selected patients with refractory tachyarrhythmias 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Wolff-Parkinson-White Syndrome--current views.

The American journal of medicine, 1977

Research

Flecainide in the Wolff-Parkinson-White syndrome.

The American journal of cardiology, 1992

Research

Current management of the Wolff-Parkinson-White syndrome.

Journal of cardiac surgery, 1993

Research

[Oral propranolol in Wolff-Parkinson-White syndrome. Electrophysiological data].

Archives des maladies du coeur et des vaisseaux, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.